Abbreviations nAChR: Nicotinic acetylcholine receptor ; VSSC: Voltage sensitive sodium chnnels ; VSCC: Voltage-sensitive calcium channels ; CF: Cimicifugoside ; MMA : Mecamylamine ; BR: Bradykinin receptors Neuropharmacology This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward.
JPET#62331
Estrogen plays an important role in differentiation, proliferation, homeostasis, and female reproductive functions. The long term genomic effects of estrogen are known to be mediated by the binding of estrogen to intracellular receptors. The activated estrogen-receptor complex then acts as a transcription factor that induces the transcription of target gene and protein synthesis. In addition to the known genomic activities, the action of steroids on neuronal functions has been reported to consist of two distinct genomic and nongenomic mechanisms (McEwen, 1991) . In several reports, nongenomic effects of steroid hormone were investigated, for example, on Ltype voltage-sensitive calcium channels (VSCCs) (Nakajima et al., 1995; Ruehlmann et al., 1998; Yamamoto, 1995; Kim et al., 2000b) , purinergic receptors (P2X 7 ) (Cario et al., 1998) , nicotinic acetylcholine receptors (nAChRs) (Uki et al., 1999) , and Maxi-K + channels (Valverde et al., 1999) . We also have shown that 17β-estradiol inhibited L-and N-type voltage sensitive calcium channels and P2X 2 receptors in PC12 cells (Kim et al., 2000a) . The nongenomic effects are characterized by a rapid time course (<10min) and a high insensitivity of signals to inhibitors of gene expression (Dar and Zinder, 1997; Wehling, 1997; Nemere and Farach-Carson, 1998) . Although the effects of estrogen on various cell types have been extensively studied, relatively little attention has been paid to effects of phytoestrogen in neuroendocrine cells.
Bovine adrenal chromaffin cells are neuroendocrine cells that have been widely
This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on February 2, 2004 as DOI: 10.1124 at ASPET Journals on November 13, 2017 jpet.aspetjournals.org Downloaded from used as a model system for the study of catecholamine secretion (Kilpatrik et al., 1982; 1980) . When acetylcholine secreted from splanchnic nerve terminal binds to acetylcholine receptors on adrenal chromaffin cell, influx of extracellular cation such as sodium and calcium through AChRs occurred and cell membrane is depolarized.
Then, the depolarization activates voltage-sensitive calcium channels that increase intracellular free Ca 2+ concentration ([Ca 2+ ] i ). Finally, increased intracellular Ca 2+ triggers exocytotic machineries to evoke catecholamine secretion. Catecholamines such as dopamine, norepinephrine, and epinephrine are synthesized in the brain, chromaffin cells, sympathetic nerves, and sympathetic ganglia and play important roles in stress and emotional behavior (Cooper et al., 1991) . Many psychotropic drugs are known to act in catecholamine-containing neurons (Seeman and Van Tol, 1994) . Therefore, compounds that modulate catecholamine secretion may be used as potential therapeutic drugs for the treatment of affective disorders.
Since cimicifugoside, a triterpene glycoside whose biological function has not been studied well, is the main ingredient of Cimicifuga Racemosa (commom name:
Black Cohosh), we investigated the effect of cimicifugoside in the catecholamine secretion from bovine adrenal chromaffin cells. Due to its steroid backbone structure, cimicifugoside has been called phytoestrogen on some occasions (Fig. 1 ).
We found that cimicifugoside, a member of phytoestrogen, specifically and JPET#62331 6 nongenomically inhibits nAChR-mediated effects evoked by DMPP, thereby leading to the inhibition of nAChR-mediated sodium, calcium increase and catecholamine secretion.
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Preparation of chromaffin cells
Chromaffin cells were isolated from bovine adrenal medulla by two-step collagenase digestion as previously described (Kilpatrik et al., 1980) . For the measurement of catecholamine secretion and the [ 3 H] nicotine binding assay, cells were plated in 24-well plates at a density of 5×10 5 cells/well. Chromaffin cells transferred to 100mm culture dishes (1×10 7 cells per dish) were used to measure cytosolic free calcium and sodium concentrations. The cells were maintained in Dulbeco's modified Eagles Medium/F-12 (Life Technologies Inc., Grand Island, NY, JPET#62331 8 USA) containing 10% bovine calf serum (Hyclone, Logan, UT, USA) and 1% antibiotics (Life Technologies Inc.). Chromaffin cells were incubated in a humidified atmosphere of 5% CO 2 /95% air at 37°C for 3-5 days before use.
Measurement of catecholamine secretion by HPLC
Catecholamine secretion from chromaffin cells was measured in 24-well plates following the method reported previously (Eaton et al., 2000; Cheng et al., 1992; 1993 solutions were used as standards.
Amperometric measurement of exocytosis
Recordings were performed at room temperature as described previously (Kim et al., 2000a) . Chromaffin cells were buffered with amine-free solution containing: 137.5mM NaCl, 2.5mM KCl, 2mM CaCl 2 , 1mM MgCl 2 , 10mM D-glucose, 10mM HEPES, pH 7.3 titrated by NaOH. Carbon-fiber electrodes were fabricated from 5 to 11µm carbon fibers (PAN T650 or P25: Amoco Performance Products) and polypropylene 10µl micropipettor tips. A carbon-fiber electrode, back-filled with 3M KCl to connect to the headstage, was attached to a single cell. Measurements were begun after this electrode current fell below 10 pA. The amperometric current, generated by oxidation of catecholamines, was measured using an axopatch 200B amplifier (Axon Instruments Inc., Foster City, CA, USA) and operated in the voltageclamp mode at a holding potential of +650 mV. Amperometric signals were low-pass filtered at 1 kHz, then sampled 0.5 kHz. For data acquisition and analysis, pCLAMP 8 software (Axon Instruments Inc., Foster City, CA, USA) was used as well as IGOR software (WaveMetrics) especially for visualizing large amounts of numeric data. 
Solutions were exchanged by a local perfusion system that allows complete

[Na + ] i measurement and whole-cell patch clamp
Cytosolic free Na + concentration ([Na + ] i ) was measured using the fluorescent Na + indicator SBFI as previously described in the report (Park et al., 1999a) . In brief, the chromaffin cell suspension was incubated in fresh DMEM/F-12 medium containing 15µM SBFI/AM, 10% bovine calf serum, and 0.2% Pluronic F-127 for 2h at 37°C with continuous stirring. The cells were then washed twice with fresh DMEM/F-12 medium HEPES titrated to pH 7.3 with CsOH. Currents were filtered at 1 kHz, and then sampled at 5 kHz.
Step pulses were applied from 0 mV to -120 mV for 360 ms with an interpulse interval of 1 s and voltage ramp was performed from -120 mV to +50 mV for 250 ms to show voltage-current relationship of nAChRs. For data acquisition and analysis, pCLAMP 8 software (Axon instruments, Foster City, CA) was used.
Solutions were exchanged by a local perfusion system that allows complete exchange of medium bathing the cells within 2 s. This article has not been copyedited and formatted. The final version may differ from this version. 
[ 3 H] nicotine binding analysis
Binding of [ 3 H] nicotine to intact cells was measured as previously described (Kilpatrik et al., 1982) . Intact chromaffin cells in 24-well plate (5 × 10 5 cells/well) were washed twice with Locke's solution. They were incubated with 40nM [ 3 H] nicotine and various concentrations of cimicifugoside for 40 min at 25°C. Then the cells were washed once with 2ml Ca 2+ -free Locke's solution containing 100µM EGTA. Finally, the cells were lysed and scraped in 0.5ml of ice-cold 5% trichloroacetic acid and radioactivity was measured by liquid scintillation counter. Nonspecific binding, determined by coincubation with 1mM nicotine, amounted to less than 20% of total binding, and was routinely subtracted from the total binding. The binding data were analyzed and expressed as percentage of total binding.
Statistical analysis
All quantitative data were expressed as means ± SEM. Half maximal inhibitory concentration (IC 50 ) values were calculated with the MicroCal Origin for Window program.
Results
Inhibitory effect of cimicifugoside on nAChR-mediated exocytosis
To study the effect of cimicifugoside on DMPP-evoked catecholamine secretion, we treated chromaffin cells with cimicifugoside (from 1 to 100µM) and the quantification was performed by HPLC ( Fig. 2) . Cimicifugoside by itself did not induce catecholamine secretion (data not shown). Values of basal catecholamine (norepinephrine) release in the absence of 10µM DMPP were 3.8 ± 0.4µM per 5×10 5 cells. 10µM DMPP evoked norepinephrine secretion up to 27.9 ± 0.1µM. In case of preincubation with cimicifugoside for 10min, the induction values were decreased with concentration dependent manner (Fig 2A) , but not in case of 60mM KCl-induced secretion ( Fig 2B) . In addition, we could observe the same inhibition phenomenon in 5min preincubation (data not shown). In order to better understand how cimicifugoside inhibits secretory response evoked by nicotinic stimulation, catecholamines secreted from single bovine chromaffin cell were measured using the amperometric method (Venton et al., 2002; Michael and Wightman, 1999) . When a brief pulse (20 s) of 10µM DMPP was applied to a single chromaffin cell, a fast and transient increase in current occurred (Fig. 3A) . Addition of 60µM cimicifugoside for 5min before and during the DMPP pulse reduced the catecholamine secretion to 32 ± This article has not been copyedited and formatted. The final version may differ from this version. 5% ( Fig. 3A and C) . The cimicifugoside-induced inhibitory effect was partially reversed after washout of cimicifugoside (Fig. 3A) . In contrast, cimicifugoside did not inhibit 60mM KCl-induced catecholamine secretion ( Fig. 3B and D) .
Inhibitory effect of cimicifugoside on nAChR-mediated calcium increase
Since the increase in [Ca 2+ ] i is an essential step in the catecholamine secretion process, we investigated the effect of cimicifugoside on the [Ca 2+ ] i increase.
Cimicifugoside (up to 300μM) by itself had no effect on [Ca 2+ ] i (data not shown), whereas 10µM DMPP induced a prominent rise in [Ca 2+ ] i (trace a in Fig. 4A ) and the calcium increase was inhibited by cimicifugoside (trace b and c in Fig. 4A ) in a concentration-dependent manner with a half-maximal inhibitory concentration (IC 50 ) of 18 ± 2µM (Fig. 4B ). We have observed the inhibitory effect of cimicifugoside on calcium increase evoked by nicotine with similar potency (Fig. 10B ). Incubation of cells with 300µM cimicifugoside resulted in the complete inhibition of DMPP-induced calcium increase. In order to assess the mechanism of cimicifugoside action we investigated the effects of different concentration of DMPP in the presence of 20µM cimicifugoside ( Fig. 4C ). We could observe half maximal inhibitory effect of cimicifugoside in each concentration of DMPP. We then examined the time course of the cimicifugoside effect on the 10µM DMPP-induced [Ca2+]i elevation (Fig. 4D ). When the cells were treated with 60µM cimicifugoside and 10μM DMPP simultaneously, there was no inhibition on [Ca 2+ ] i rise. In addition, the result shows that the inhibition effect of cimicifugoside was influenced by the preincubation time and that at least 3 min of incubation appears to be necessary to exert the maximal cimicifugoside effect. We also monitored calcium increase in single chromaffin cell using multiphoton confocal microscopic calcium imaging (Fig. 5 ). In the confocal image of when the cells were treated with 60μM cimicifugoside for 5min, in the presence of 10µM DMPP the fluorescence intensity of the confocal image was remarkably reduced when 10μM DMPP was applied (Fig. 5A ). In contrast, cimicifugoside did not affect KCl-evoked calcium entry (Fig. 5B ).
Receptor specificity of cimicifugoside
The specificity of cimicifugoside-induced inhibition was examined by testing the effects of cimicifugoside on voltage-sensitive calcium channels (VSCCs), voltagesensitive sodium channels (VSSCs), and phospholipase C (PLC)-linked bradykinin receptor (B2R) signaling. As shown in Fig. 6 , calcium increase induced by 50mM KCl was not inhibited by pretreatment with 20μM cimicifugoside, suggesting that voltagesensitive calcium channels were not affected by cimicifugoside. Veratridine is a plant alkaloid that opens voltage-sensitive sodium channels by binding to the pharmacological site 2 on the sodium channels and slowing its inactivation (Catterall, 1980) . In bovine chromaffin cells, veratridine-induced activation of sodium channels was known to cause membrane depolarization (Friedman et al., 1985; Kitayama et al., 1990 ) thereby leading to slow and weak calcium increase through voltage-sensitive calcium channels (Heldman et al., 1996) . The calcium increase by veratridine was not affected by cimicifugoside, either. Bradykinin is known to activate PLC-linked B2 bradykinin receptors in bovine chromaffin cells (McMillian et al., 1992; Park et al., 1999b) . A half maximal inhibitory concentration of cimicifugoside in the DMPPinduced [Ca 2+ ] i elevation had no effect on the bradykinin-evoked calcium increase.
The data together suggested that cimicifugoside have no significant inhibitory effect on calcium channels, sodium channels, and PLC-linked receptors. Therefore, it seems that the effect of cimicifugoside on nAChR is highly specific.
Inhibitory effect of cimicifugoside on the sodium influx through the nAChR
Since both calcium channels and nAChRs were activated by nicotinic stimulation, inhibition of DMPP-induced calcium increase can result from the inhibition of nAChRs or calcium channels. In order to verify whether nAChRs are inhibited by cimicifugoside, we investigated the effect of cimicifugoside on DMPP-induced sodium increase that occurs only through nAChRs. As shown in Fig. 7 , DMPP induced an Fig. 7A ). The inhibitory effect of cimicifugoside on the sodium current through nAChRs was also measured by whole-cell patch clamp recording (Fig. 7C,D,and E) . The sodium currents induced by 10μM DMPP were remarkably reduced when the cells were costimulated with 3μM or 60μM cimicifugoside. The inhibition concentration of sodium influx by cimicifugoside was similar to those by 17β-estradiol, but less effective than by prototype antagonist mecamylamine (data not shown). The results suggested that the inhibition of DMPP-induced sodium increase by cimicifugoside result from the direct inhibition of nAChRs.
Nicotine binding
Since nicotine works on nAChR as a ligand we tested whether the binding of [ 3 H]nicotine to nAChRs was inhibited by cimicifugoside. We previously demonstrated clozapine showed concentration dependent competition with [ 3 H]nicotine in the same condition (Park et al., 2001) . As shown in Fig. 8 , cimicifugoside did not significantly compete for binding with [ 3 H]nicotine, suggesting that its binding site is distinct from that of agonist including nicotine and acetylcholine. 
Comparison of inhibitory effects among cimicifugoside and other antagonists
It has been reported that local anesthetics such as lidocaine, procaine, QX-222 inhibit the function of nAChRs in a noncompetitive manner (Gentry and Lukas, 2001) .
Therefore, we compared the inhibitory potency of cimicifugoside with that of lidocaine and prototype antagonist mecamylamine under experimental conditions. As shown in Fig. 9 , all of them inhibited DMPP-induced calcium increase in which the most potent agent was mecamylamine and lidocaine was the less potent. We determined whether cimicifugoside had subtype specificity. Intracellular calcium was evoked by 5-lodo-A-85380 and UB165 which are selective agonists to α 4β2 and α 3β2, respectively (Fig.   10A ). Due to UB165 had more potent effect on calcium increase (EC 50 : 40nM) than A-85380 (EC 50 : 90nM), presumably α 3β2 type nAChRs may be more expressed than α 4β2 types in bovine adrenal chromaffin cell. Maximum calcium induction by selective agonists we tested, as well as DMPP and nicotine, were inhibited by cimicifugoside with similar potency (Fig. 10B) . The results suggested that CF is broad spectrum nAChR inhibitor. 
Discussion
Cimicifuga racemosa was historically used by the American indians to assist and ease the pain of childbirth, and also as an antidote against snake bites. It is an antispasmodic herb that can relieve cramps in the pelvic area while increasing blood supply to this area. It is used to treat for painful periods with cramps and any inflammatory condition in the pelvic area associated with spasm, tension or uterine discharge. It is also used in the treatment of nerve pain, headaches, arthritic pain and inflammation (British Herbal Pharmacopoeia, 1983) . Recently the extract of C.
Racemosa containing phytoestrogen has been used to treat menopausal women.
Phytoestrogens such as isoflavone extracted from soybean has been mostly highlighted as an agent for hormone replacement therapy (HRT) of estrogen deficiency in menopausal women. Most of women are experiencing menopausal symptoms caused by estrogen deficiency which results in hyperactivity of neuronal conduction such as hot flushes, the most prominent neurovegetative symptom (Ginsburg et al., 1981) . In recent study, it was reported that ethanol extract CR BNO 1055 of C. Racemosa was more effective in release of menopausal symptom than another phytoestrogen-containing candidates (Wuttke et al., 2003; Jarry et al., 2003) .
Although cimicifugoside is an important phytoestrogen ingredient of C. Racemosa, This article has not been copyedited and formatted. The final version may differ from this version. little study has been conducted so far to elucidate its action mechanism.
Our data clearly suggest that catecholamine secretion induced by nicotinic acetylcholine receptor-mediated stimulation is specifically inhibited by cimicifugoside and that these inhibitory effects are caused by the inhibition of sodium influx through ionotropic receptor, nAChRs. The reason why the IC 50 of cimicifugoside on sodium increase (2µM) was considerably lower than that on calcium rise(18µM) may be that electrophysiologically higher concentration of antagonist is needed to suppress the activation of voltage-sensitive calcium channels compare to that needed to suppress sodium current. In other words, the amount of cimicifugoside sufficient to inhibit intracellular sodium increase can be insufficient to inhibit calcium rise. In addition, we observed that cimicifugoside inhibits cytosolic calcium increase a downstream phenomenon of membrane depolarization caused by the activation of nAChRs, and those other direct pathways which could activate voltage-sensitive calcium channels are not significantly influenced by cimicifugoside. Although calcium channels are activated in the activation process of nAChRs, both the inhibition of DMPP-induced sodium increase and the absence of inhibitory effect on high K + -induced calcium increase clearly indicated that nAChRs, but not calcium channels, are the specific calcium increase. Both 5-lodo-A-85380-and UB165-induced calcium rise was inhibited by cimicifugoside to similar extents, suggesting that cimicifugoside did not have specificity for a certain type of nAChR. Even we used quite high concentration of cimicifugoside(>50µM) to visualize its inhibitory effect, considering the amount (2.5% triterpene glycosides of total extract) among ingredients of C. racemosa, the concentration may be reached in clinical reality. In addition, the applicable dose for local anesthetics, such as lidocaine can be converted to micromolar range for its effective working.
In contrast to rapid onset inhibitors such as borneol (Park et al., 2003) , cimicifugoside exhibits a rather slow onset, requiring at least 3 min of preincubation, suggesting that cimicifugoside does not interact directly with extracellular domain of nAChRs. According to the inhibition of calcium induction by selective agonist, it seems to lack receptor subtype selectivity, but functions as a broad spectrum inhibitory modulator. Furthermore, lack of inhibition by cimicifugoside in [ 3 H]nicotine binding to nAChRs indicate that cimicifugoside acts as a noncompetitive inhibitor of nAChR. A variety of pharmacological agents are known to modulate the transitions between conformations by directly binding to several sites on nAChRs that are topographically distinct from the acetylcholine binding sites (Lena and Changeux, 1993) . Many physiological or pharmacological effectors modify the properties of nAChRs even though they do not significantly affect the binding of agonist such as acetylcholine and nicotine. These molecules, known as noncompetitive blockers, inhibit the ion channel gating activity of the nAChRs through mechanisms that differ from those of the competitive blockers (Lowenick et al., 2001) . Our data suggest that cimicifugoside is likely to act as a noncompetitive blocker of nAChRs. In chromaffin cell it has been reported previously that a synthetic glucocorticoid, dexamethasone, binds to the specific site located on the outer cell membrane, and suppresses the I Ach level in a noncompetitive manner, and that steroids may change the lipid environment of nAChRs, thus leading to the suppression of I Ach. In other words, it is possible that the structure of steroids, which is changed by the cleavage of cholesterol side chain, thus contributes to the direct inhibition of nAChRs by steroids (Uki et al., 1999; Inoue and Kuriyama, 1989 ). On the same principle, cimicifugoside seems to act like other steroids because it has a similar inhibitory potency of 17β-estradiol against intracellular sodium increase induced by DMPP in our condition (data not shown).
The mechanism of action of steroid hormones can be classified as genomic and nongenomic, depending on whether the hormone binds to intracellular receptors and causes transcriptional activation. Nongenomic effects do not conclude gene expression but result in modulation of cellular event such as exocytosis (Machado et al., 2002) . Whereas at least 30min are required for the genomic response to estrogen This article has not been copyedited and formatted. The final version may differ from this version. to occur, the inhibition of the stimulant-induced [Ca 2+ ] i rise following cimicifugoside treatment occurs within 5min. In consideration of effective incubation time, the action of cimicifugoside to nAChRs could be the nongenomic action of phytoestrogen. In several reports, nongenomic effects of estrogen were investigated, for example, on voltage-sensitive calcium channels (VSCCs), purinergic receptors, ionotrophic receptors, and Maxi-K + channels, but in case of phytoestrogen, little attention has been paid to their role as bioactive materials in cellular signal transduction system.
The specific inhibition on nAChR-mediated effects by cimicifugoside may contribute to the understanding of the basic mechanism of phytoestrogen effects as medicine, and may be classified as the general action of steroid on membrane receptors reported previously. Furthermore, its specific action implicates cimicifugoside as a potential candidate for therapeutic agents. Clinical agents such as local anesthetics, products that alleviate symptoms of nicotine withdrawal or agent that release hyperactivation of sympathetic nerves were shown to inhibit functions of nAChRs, although the correlation between the inhibitory effect and its clinical function
is not yet clear. In addition, the relationship between nAChR inhibition of cimicifugoside and the alleviation of climacteric/menopausal symptoms is still unclear.
The determination of cimicifugoside's inhibition mechanism on nAChR and its potential clinical application are subjects of interest for further study and 
